Trial Profile

Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAG-17 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms CREATION

Most Recent Events

24 Apr 2025 Status changed from recruiting to completed.
09 Apr 2025 Results presented in a Ractigen Therapeutics media release.
09 Apr 2025 According to a Ractigen Therapeutics media release, results from this trial presented during an oral presentation at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego, CA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com